Patents by Inventor Kirk E. Fry
Kirk E. Fry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8148067Abstract: The invention presents a method of diagnosing or monitoring the status of systemic lupus erythematosus (SLE) in a subject or patient comprising detecting the expression of all genes of a diagnostic set in the subject or patient wherein the diagnostic set comprises two or more genes having expression correlated with the classification or status of SLE; and diagnosing or monitoring the status of SLE in the subject or patient by applying at least one statistical method to the expression of the genes of the diagnostic set.Type: GrantFiled: November 9, 2007Date of Patent: April 3, 2012Assignee: Xdx, Inc.Inventors: Preeti G. Lal, Gavin E. Williams, Kirk E. Fry, Jingtao Sun, Russell L. Dedrick
-
Patent number: 7785797Abstract: Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described.Type: GrantFiled: August 19, 2009Date of Patent: August 31, 2010Assignee: XDx, Inc.Inventors: Jay Wohlgemuth, Kirk E. Fry, Robert Woodward, Ngoc Ly, James Prentice, Macdonald Morris, Steven Rosenberg
-
Publication number: 20090298060Abstract: The invention presents a method of diagnosing or monitoring the status of systemic lupus erythematosus (SLE) in a subject or patient comprising detecting the expression of all genes of a diagnostic set in the subject or patient wherein the diagnostic set comprises two or more genes having expression correlated with the classification or status of SLE; and diagnosing or monitoring the status of SLE in the subject or patient by applying at least one statistical method to the expression of the genes of the diagnostic set.Type: ApplicationFiled: November 9, 2007Publication date: December 3, 2009Applicant: XDX, Inc.Inventors: Preeti G. LAL, Gavin E. Williams, Kirk E. Fry, Jingtao Sun, Russell L. Dedrick
-
Patent number: 7604936Abstract: Methods of diagnosing or monitoring auto immune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring auto immune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis and kits or systems containing the same are also described.Type: GrantFiled: April 24, 2003Date of Patent: October 20, 2009Assignee: XDX, Inc.Inventors: Jay Wohlgemuth, Kirk E. Fry, Robert Woodward, Ngoc Ly
-
Publication number: 20080038746Abstract: The invention presents methods of using splice variants and reagents thereof for diagnosing and monitoring the status of transplants and immune disorders including diagnosing, monitoring and predicting transplant rejection or non-rejection, steroid responsiveness, and onset or flare of immune disorders.Type: ApplicationFiled: August 14, 2007Publication date: February 14, 2008Inventors: Steven Rosenberg, Kirk E. Fry, Bin Wu, Russel L. Dedrick
-
Patent number: 7189506Abstract: The present invention provides molecular switch system methods and compositions for use in regulatable gene expression. The system includes a nucleic acid construct which has a DNA response sequence for a transcriptional regulatory protein operably linked to a promoter, a compound binding sequence in the vicinity of the DNA response sequence, a transgene under the control of the promoter; and a DNA binding compound. In some cases, the molecular switch system further includes a nucleic acid sequence encoding a transcriptional regulatory protein operably linked to a second promoter. The invention further provides a method for screening compounds for the ability to function in the molecular switch system and thereby regulate gene expression.Type: GrantFiled: March 3, 2000Date of Patent: March 13, 2007Assignee: Genelabs Technologies, Inc.Inventors: Moon Young Lim, Cynthia A. Edwards, Kirk E. Fry, Thomas W. Bruice, Douglas B. Starr, Megan E. Laurance, Yan Kwok, Albert W. Tam
-
Patent number: 7094406Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: May 7, 2001Date of Patent: August 22, 2006Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services and Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert W. Tam, Kirk E. Fry
-
Patent number: 6869765Abstract: The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: GrantFiled: November 13, 2001Date of Patent: March 22, 2005Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
-
Publication number: 20030124510Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: ApplicationFiled: May 7, 2001Publication date: July 3, 2003Applicant: The United States of America, The Secretary of the Department of Health and Human ServicesInventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert W. Tam, Kirk E. Fry
-
Publication number: 20030124530Abstract: The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: ApplicationFiled: November 13, 2001Publication date: July 3, 2003Applicant: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
-
Patent number: 6384208Abstract: The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: GrantFiled: July 15, 1999Date of Patent: May 7, 2002Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
-
Patent number: 6379891Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: April 19, 2000Date of Patent: April 30, 2002Assignees: The United States of America as represented by the Department of Health and Human Services, Genelabs Technologies, Inc.,Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry
-
Patent number: 6229005Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: August 3, 1998Date of Patent: May 8, 2001Assignees: The United States of America as represented by the Department of Health and Human Services, Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert W. Tam, Kirk E. Fry
-
Patent number: 6120988Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: June 7, 1995Date of Patent: September 19, 2000Assignees: Genelabs Technologies, Inc., The United States of AmericaInventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry
-
Patent number: 6010849Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: GrantFiled: June 7, 1995Date of Patent: January 4, 2000Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
-
Patent number: 5874563Abstract: Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.Type: GrantFiled: June 5, 1995Date of Patent: February 23, 1999Assignee: Genelabs Technologies, Inc.Inventors: Jungsuh P. Kim, Kirk E. Fry, Lavonne Marie Young, Jeffrey M. Linnen, John Wages
-
Patent number: 5869241Abstract: The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: GrantFiled: June 7, 1995Date of Patent: February 9, 1999Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
-
Patent number: 5856134Abstract: Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.Type: GrantFiled: June 5, 1995Date of Patent: January 5, 1999Assignee: Genelabs Technologies, Inc.Inventors: Jungsuh P. Kim, Kirk E. Fry, LaVonne Marie Young, Jeffrey M. Linnen, John Wages
-
Patent number: 5849532Abstract: Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G Virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.Type: GrantFiled: June 6, 1995Date of Patent: December 15, 1998Assignee: Genelabs Technologies, Inc.Inventors: Jungsuh P. Kim, Kirk E. Fry, LaVonne Marie Young, Jeffrey M. Linnen, John Wages
-
Patent number: 5824649Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: June 7, 1995Date of Patent: October 20, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry